Japan's Takeda nears breakthrough in treating narcolepsy

TOKYO -- Japan's Takeda Pharmaceuticals has drawn closer to offering a first-of-its-kind treatment for narcolepsy, with the final phase of clinical studies set to launch this fall.

Takeda presented its findings from a Phase 2 trial of drug candidate TAK-861 during the joint annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society held early this month.